GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

Home・Elenco Azioni・AstraZeneca PLC
Search

AstraZeneca PLC

Chiusa

SettoreSettore sanitario

13,514 -3.07

Fortemente da comprare

Aggiornamento del prezzo 1 mag 2026, 15:29 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13514

Massimo

13632

Metriche Chiave

By Trading Economics

Entrata

1.6B

3.9B

Vendite

-215M

15B

P/E

Media del settore

27.389

51.415

EPS

1.29

Rendimento da dividendi

1.75

Margine di Profitto

25.602

Dipendenti

96,100

EBITDA

1.1B

5.7B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+17.01% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.75%

2.34%

Utili prossimi

27 lug 2026

Prossima data del' Ex Dividendo

6 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-8.7B

282B

Apertura precedente

13517.07

Chiusura precedente

13514

Notizie sul Sentiment di mercato

By Acuity

26%

74%

53 / 345 Classifica in Healthcare

AstraZeneca PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 16:28 UTC

Utili

Correction to AstraZeneca Update

DJ

LeggI

29 apr 2026, 15:11 UTC

Utili

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

DJ

LeggI

29 apr 2026, 06:31 UTC

Utili

AstraZeneca Gets Revenue Boost From Cancer Drugs

DJ

LeggI

27 mar 2026, 10:04 UTC

Principali Notizie su Eventi

Oil Climbs Higher, Stock Recovery Fades as Doubts Cloud Cease-Fire Hopes

DJ

LeggI

13 mag 2026, 12:29 UTC

Discorsi di Mercato

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

DJ

LeggI

13 mag 2026, 11:54 UTC

Discorsi di Mercato

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

DJ

LeggI

1 mag 2026, 09:31 UTC

Discorsi di Mercato

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

DJ

LeggI

29 apr 2026, 10:29 UTC

Discorsi di Mercato
Utili

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

DJ

LeggI

29 apr 2026, 10:06 UTC

Discorsi di Mercato
Utili

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

DJ

LeggI

29 apr 2026, 09:53 UTC

Discorsi di Mercato
Utili

AstraZeneca Seems in Fine Health -- Market Talk

DJ

LeggI

29 apr 2026, 06:05 UTC

Utili

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

DJ

LeggI

29 apr 2026, 06:04 UTC

Utili

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

DJ

LeggI

29 apr 2026, 06:04 UTC

Utili

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

DJ

LeggI

29 apr 2026, 06:03 UTC

Utili

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

DJ

LeggI

29 apr 2026, 06:03 UTC

Utili

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

DJ

LeggI

29 apr 2026, 06:02 UTC

Utili

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

DJ

LeggI

29 apr 2026, 06:01 UTC

Utili

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

DJ

LeggI

29 apr 2026, 06:01 UTC

Utili

AstraZeneca Backs 2026 View

DJ

LeggI

29 apr 2026, 06:00 UTC

Utili

AstraZeneca PLC 1Q Adj EPS $2.58

DJ

LeggI

29 apr 2026, 06:00 UTC

Utili

AstraZeneca PLC 1Q Rev $15.29B

DJ

LeggI

29 apr 2026, 06:00 UTC

Utili

AstraZeneca PLC 1Q Pretax Pft $3.91B

DJ

LeggI

29 apr 2026, 06:00 UTC

Utili

AstraZeneca PLC 1Q Oper Pft $4.25B

DJ

LeggI

29 apr 2026, 06:00 UTC

Utili

AstraZeneca PLC 1Q Net Pft $3.08B

DJ

LeggI

29 apr 2026, 06:00 UTC

Utili

AstraZeneca PLC 1Q EPS $1.97

DJ

LeggI

27 apr 2026, 10:48 UTC

Discorsi di Mercato

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

DJ

LeggI

10 apr 2026, 11:57 UTC

Discorsi di Mercato

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

DJ

LeggI

10 apr 2026, 10:26 UTC

Discorsi di Mercato
Utili

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

DJ

LeggI

2 apr 2026, 09:16 UTC

Discorsi di Mercato

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

DJ

LeggI

27 mar 2026, 10:40 UTC

Discorsi di Mercato

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

DJ

LeggI

27 mar 2026, 10:17 UTC

Discorsi di Mercato

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

DJ

LeggI

Confronto tra pari

Modifica del prezzo

AstraZeneca PLC Previsione

Obiettivo di Prezzo

By TipRanks

17.01% in crescita

Previsioni per 12 mesi

Media 16,076.92 GBX  17.01%

Alto 18,600 GBX

Basso 11,300 GBX

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AstraZeneca PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

13

Acquista

1

Mantieni

1

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a AstraZeneca PLC - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

53 / 345 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Altri titoli del settore

GSK

GlaxoSmithKline PLC

1,858.5

↓-0.83%
help-icon Live chat